A Phase 2, Randomized, Open-label (With Blinded Plasminogen Activator and Placebo Control Groups) Study to Evaluate the Effects of Different Intra-thrombus Infusion Regimens of Plasmin (Human) Compared to Plasminogen Activator and Placebo In Patients With Acute Lower Extremity Native Artery or Bypass Graft Occlusion

Trial Profile

A Phase 2, Randomized, Open-label (With Blinded Plasminogen Activator and Placebo Control Groups) Study to Evaluate the Effects of Different Intra-thrombus Infusion Regimens of Plasmin (Human) Compared to Plasminogen Activator and Placebo In Patients With Acute Lower Extremity Native Artery or Bypass Graft Occlusion

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Jun 2017

At a glance

  • Drugs Fibrinolysin human (Primary) ; Plasminogen activator enzymes
  • Indications Embolism and thrombosis; Peripheral arterial occlusive disorders
  • Focus Therapeutic Use
  • Sponsors Grifols; Talecris Biotherapeutics
  • Most Recent Events

    • 09 May 2016 This trial is completed in Slovakia, Bulgaria and Prematurely ended in Hungary and Spain according to European Clinical Trials Database record.
    • 04 May 2016 This trial is completed in Czech republic (end date: 03 Sep 2014), according to the European Clinical Trials Database.
    • 27 Apr 2016 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top